Researchers track leukemia drug in Kids' blood to Fine-Tune treatment
NCT ID NCT07221656
Summary
This study aims to measure how long a specific leukemia drug (calaspargase pegol) stays at an effective level in children's blood after it is given. It will involve about 20 children and young adults with acute lymphoblastic leukemia or lymphoma. The researchers also want to see if having higher drug levels is linked to more side effects, which could help make future treatments safer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.